Mohamed Javid Raja Iyub

Dr. Mohamed Javid Raja Iyub


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2025 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
DSDeerush Kannan Sakthivel
Deerush Kannan Sakthivel
PPPushan Prabhakar
Pushan Prabhakar
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
RGRohan Garje
Rohan Garje
MMMurugesan Manoharan
Murugesan Manoharan

29 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MGMohammad Arfat Ganiyani
Mohammad Arfat Ganiyani
HNHiba Narvel
Hiba Narvel
AAArjun Pon Avudaiappan
Arjun Pon Avudaiappan
MTMrudula Thiriveedi
Mrudula Thiriveedi
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
RGRohan Garje
Rohan Garje
Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30–40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC. However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood. Methods: We conducted a retrospective cohort study of patients with metastatic non-clear-cell RCC. Patients were stratified by receipt of CN. Baseline demographic, clinical, histologic, and metastatic site variables were collected. Overall survival was analyzed using Kaplan–Meier methods and compared with the log-rank test. Cox proportional hazards regression was performed to identify independent predictors of survival, including CN, systemic therapy, year of diagnosis, histology, and metastatic sites. Results: Among 2753 patients with metastatic nccRCC, 1654 (60.1%) underwent CN and 1099 (39.9%) did not undergo CN. The 2-year and 5-year OS rates were 35.52% and 19.22% in the CN group versus 18.53% and 7.47% in the non-CN group (p < 0.001). In the doubly robust IPTW-weighted multivariable Cox regression analysis, CN was associated with improved overall survival, corresponding to a 40% lower risk of death compared with no CN (HR 0.60, 95% CI 0.54–0.66; p < 0.001). Additionally, more recent treatment eras were associated with progressively improved overall survival, with patients diagnosed between 2015 and 2017 and 2018 onward demonstrating significantly improved OS compared with those diagnosed between 2004 and 2014. Conclusions: Our study demonstrates that CN was associated with improved OS in patients with non-clear-cell mRCC by reducing the risk of death by 40% after adjusting for baseline characteristics. These findings emphasize the role of CN even in the IO-TKI era for the management of patients with non-clear-cell mRCC. However, these findings should be interpreted in the context of the retrospective study design, potential selection bias, and lack of granular systemic therapy data within the NCDB.

16 September 2025 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
DSDeerush Kannan Sakthivel
Deerush Kannan Sakthivel
PPPushan Prabhakar
Pushan Prabhakar
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
MOManuel Ozambela
Manuel Ozambela
MMMurugesan Manoharan
Murugesan Manoharan

11 November 2025 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
RIRaja Iyub
Raja Iyub
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
PPPushan Prabhakar
Pushan Prabhakar
DSDeerush Kannan Sakthivel
Deerush Kannan Sakthivel
ACAditi Chandrasekaran
Aditi Chandrasekaran
MMMurugesan Manoharan
Murugesan Manoharan

4 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
PPPushan Prabhakar
Pushan Prabhakar
DSDeerush Kannan Sakthivel
Deerush Kannan Sakthivel
JPJasmine Pelia
Jasmine Pelia
VSVivek Sanker
Vivek Sanker
MMMurugesan Manoharan
Murugesan Manoharan
Background: Robot-assisted partial nephrectomy (RAPN) can be done using either a three-arm or four-arm configuration. However, the evidence comparing the perioperative, functional, and oncological outcomes between these two approaches is inconsistent. Therefore, we aimed to quantitatively compare the outcomes of three-arm versus four-arm RAPN. Methods: A comprehensive search of multiple databases, including PubMed, Embase, Scopus, Web of Science, and Cochrane, was conducted, adhering to the PRISMA guidelines. Studies comparing three-arm and four-arm RAPN were included. Continuous outcomes were assessed using mean differences (MD), and dichotomous outcomes were evaluated using risk ratios (RR). The ROBINS-I tool was used to determine the risk of bias. Results: Five studies that met the selection criteria were included in the final review and analysis. The pooled analyses demonstrated no significant difference in estimated blood loss, warm ischemia time, transfusion rates, overall complications, major complications, or positive surgical margins between the three-arm and four-arm RAPN. Although the initial primary analysis showed a shorter length of stay within the three-arm RAPN technique, the sensitivity analysis did not reflect this finding. Conclusions: The three-arm and four-arm RAPN demonstrated comparable perioperative, functional, and oncologic outcomes. As both techniques appear to be effective, the choice of configuration may be decided by the institutional resources, case complexity, and the surgeon’s preference.

1 April 2025 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
MIMohamed Javid Raja Iyub
Mohamed Javid Raja Iyub
MEMahmoud Eldefrawy
Mahmoud Eldefrawy
SSSai Raghavendra Sridhar
Sai Raghavendra Sridhar
MRMukesh Roy
Mukesh Roy
MRMuni Rubens
Muni Rubens
MMMurugesan Manoharan
Murugesan Manoharan